Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Rheumatoid Arthritis
•
TNF Inhibitors
•
Cardiology
•
Cardio-Rheumatology
Would you be hesitant to continue a TNF inhibitor in a patient with stable RA and a history of COPD, Cor Pulmonale, severe reduced RVEF, but LVEF 65%?
Related Questions
Do you pursue coronary artery calcium scoring in patients with metabolic risk factors and autoimmune disease in order to guide decisions regarding GLP-1 medications?
How do you approach management of recurrent idiopathic pleuropericarditis?
In a patient with psoriatic arthritis and recurrent pericarditis, would you combine abatacept or other biologics with rilonacept?
How do you approach cardiovascular risk management in patients with rheumatic disease?
How do you approach treatment selection in patients with rheumatoid arthritis and severe COPD?
What factors would encourage you to choose abatacept vs tocilizumab in a patient with RA-ILD with a UIP pattern of pulmonary fibrosis?
If subdeltoid bursitis, bicipital tenosynovitis, and femoroacetabular synovitis are commonly present in PMR, why are they not included in the criteria for PMR and how are they differentiated from elderly onset RA where presentation is often atypical and more proximal?
Are you comfortable trying a different JAK inhibitor in patients with prior JAK inhibitor allergy?
How do you approach use of DMARDs and/or biologics for inflammatory arthritis in patients with a history of seizure disorder on anti-epileptic medications?
How do you approach choosing between subcutaneous and IV actemra for RA?
